Article Text
Therapeutics/Prevention
Randomised controlled trial
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease
Statistics from Altmetric.com
Footnotes
Competing interests AJS worked as a clinical investigator enrolling four participants in this double-blind placebo-controlled EMPA-REG OUTCOME trial.
Provenance and peer review Commissioned; internally peer reviewed.